FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)-Phase III double-blind placebo controlled multinational study. Meeting Abstract

International Collaboration

cited authors

  • Secord, Angeles Alvarez; Gupta, Sunil; Reddick, Cathy; Chauhan, Jyoti; Gill, Sarah; Schorge, John O.; Gold, Michael; Tewari, Devansu; Breed, Christopher A.; Braly, Patricia S.; Kuo, Dennis Yi-Shin; Modesitt, Susan C.; Holloway, Robert W.

Publication Date

  • May 20, 2021

webpage

published in

category

volume

  • 39

issue

  • 15